Wen‐Jen Hwu
319 works · 36,611 citations · h-index 60
Top works
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
- Prognostic Factors That Determine the Long-Term Survival of Patients with Unresectable Metastatic Melanoma
- Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
- Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
- Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).
- Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
- Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
- Prognostic factors for survival in melanoma patients with brain metastases
- Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
- Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
- Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
- Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature.
- Radiologic Manifestations of Immune-Related Adverse Events in Patients With Metastatic Melanoma Undergoing Anti–CTLA-4 Antibody Therapy
- Diverse types of dermatologic toxicities from immune checkpoint blockade therapy
- Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.